Aug. 26 at 6:57 PM
$BHVN $SYRE $GOVX — three biotech situations, one capital-markets lesson: balance-sheet strength changes what management can afford to do.
$BHVN is licensing Kv7 to SK for
$400M of near-term cash, plus milestones/royalties, while shifting future costs and certain obligations off its balance sheet.
$SYRE had statistically significant RA findings but decided the magnitude was not good enough to prioritize the program. It had ~
$1.145B of cash/investments at June 30. That is what optionality looks like: it can afford to stop funding “good enough.”
$GOVX had ~
$3.14M of June cash and runway only into September. It gets ~
$3.65M from exercising 5.7M warrants at
$0.64, but issues ~11.4M new 5-year warrants in return.
The signal I’m watching isn’t simply dilution. It’s negotiating leverage.
Cash lets you wait. Assets give you financing options. Weak balance sheets make liquidity expensive.
That’s where I’ve got my eyes today.
https://insidersonly.beehiiv.com/p/the-best-biotech-asset-may-be-the-ability-to-say-no
